Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Six Months ended September 30, 2026 (Q2 FY27)

Nature of Filing / Announcement: Regulatory filing under SEBI LODR Regulations 30, 33

Audit Opinion:

Clean, unqualified limited review report from B S R & Co. LLP for both standalone and consolidated results.

Key Financial Highlights [Rs. in Lakhs]:

Standalone Results:

Quarter ended September 30, 2026:

  • Revenue from Operations: ₹39,604 (vs. ₹34,441 in Q2 FY26; +15.0% YoY)
  • Total Income: ₹40,135
  • Net Profit/(Loss): (₹204) [Loss] (vs. Profit of ₹1,078 in Q2 FY26)
  • EPS: (₹0.14) Basic & Diluted (vs. ₹0.77 Basic in Q2 FY26)

Six months ended September 30, 2026:

  • Revenue from Operations: ₹77,129 (vs. ₹67,034 in H1 FY26; +15.1% YoY)
  • Total Income: ₹78,757
  • Net Profit: ₹354 (vs. Profit of ₹1,423 in H1 FY26; -75.1% YoY)
  • EPS: ₹0.24 Basic & Diluted (vs. ₹1.01 Basic in H1 FY26)

Other Standalone Metrics (as at September 30, 2026):

  • Paid-up equity share capital: ₹14,930 (Face value ₹10 each)
  • Other Equity: ₹145,548
  • Cash and Cash Equivalents: ₹3,167
  • Total Debt: Not explicitly summarized but includes Borrowings (₹28,639 non-current + ₹20,634 current) and Lease liabilities (₹47,003 non-current + ₹3,391 current)

Consolidated Results:

Quarter ended September 30, 2026:

  • Revenue from Operations: ₹73,016 (vs. ₹64,516 in Q2 FY26; +13.2% YoY)
  • Total Income: ₹73,371
  • Net Profit attributable to owners of the company: ₹479 (vs. ₹1,627 in Q2 FY26)
  • EPS: ₹0.32 Basic & Diluted (vs. ₹1.15 in Q2 FY26)

Six months ended September 30, 2026:

  • Revenue from Operations: ₹142,355 (vs. ₹125,696 in H1 FY26; +13.3% YoY)
  • Total Income: ₹144,094
  • Net Profit attributable to owners of the company: ₹1,856 (vs. ₹2,102 in H1 FY26; -11.7% YoY)
  • EPS: ₹1.24 Basic & Diluted (vs. ₹1.49 in H1 FY26)

Other Consolidated Metrics (as at September 30, 2026):

  • Paid-up equity share capital: ₹14,930
  • Other Equity: ₹119,927
  • Cash and Cash Equivalents: ₹12,018

Exceptional Items:

Standalone (Q2 FY26): A provision of ₹661 lakhs was recognized towards estimated customs duty liability and interest related to shortfall in export obligations under the EPCG scheme.

Consolidated (Q2 FY26): A provision of ₹1,159 lakhs was recognized for the same EPCG-related customs duty liability across the group.

Previous Year (FY26): The standalone statement notes exceptional items of ₹(5,538) lakhs for FY26, which included an impairment loss on investment in BACC (₹3,752 lakhs), an impairment on investment in HCG Kolkata Cancer Care LLP (₹3,000 lakhs), an impairment reversal for HCG Manavata Oncology LLP (₹2,000 lakhs), and an impact from new Labour Codes (₹786 lakhs). The consolidated statement for FY26 notes exceptional items of ₹(4,845) lakhs, which included the BACC goodwill impairment (₹3,191 lakhs) and the Labour Code impact (₹1,267 lakhs).

Corporate Actions:

  • Dividend: Not declared.
  • ESOP: The shareholders approved the HCG Employee Stock Option Scheme 2026 (HCG ESOS 2026) via postal ballot on July 8, 2026. The scheme allows a maximum of 74,21,455 options. The Nomination and Remuneration Committee, on September 9, 2026, granted 64,46,843 options to eligible employees (including Dr. Manish Mattoo, CEO). A specific grant of up to 18,55,364 options (1.24% of diluted capital) to Dr. Manish Mattoo was also approved.

Other Significant Information:

  • Segment Information: The company has a single operating segment: 'setting up and managing hospitals and medical diagnostic services'.
  • Taxation: The income tax expense for the previous year (FY26) is net of ₹1,820 lakhs relating to a reversal of income taxes from earlier years.
  • Entities: The consolidated results include 11 subsidiaries and 6 step-down subsidiaries. A list of all consolidated entities is provided in the annexure to the auditor's report.